CJC-1295 + MOTS-c Stack: Complete Protocol, Dosing, and Evidence Review

What Are CJC-1295 and MOTS-c, and Why Stack Them?

CJC-1295 and MOTS-c address metabolic health from two very different biological entry points. CJC-1295 works top-down through the hypothalamic-pituitary axis; MOTS-c works bottom-up from the mitochondrial genome. Stacking them creates parallel pressure on body composition, insulin sensitivity, and energy metabolism without requiring the peptides to share a receptor or compete for a signaling pathway.

CJC-1295: Growth Hormone Axis Stimulation

CJC-1295 is a synthetic analogue of growth-hormone-releasing hormone (GHRH) that binds the GHRH receptor on pituitary somatotrophs. The version with a Drug Affinity Complex (DAC) covalently binds albumin in plasma, extending its half-life to roughly 6 to 8 days vs. 30 minutes for native GHRH or CJC-1295 without DAC [1].

In a dose-escalation study published in the Journal of Clinical Endocrinology and Metabolism (N=65 healthy adults), a single injection of CJC-1295 with DAC at 60 mcg/kg produced mean 2- to 10-fold increases in GH area-under-the-curve and a 1.5- to 3-fold rise in IGF-1 that persisted for 6 to 14 days [1]. These elevations preserved the normal pulsatile pattern of GH secretion rather than replacing it with a flat pharmacological plateau, which is one meaningful mechanistic distinction from recombinant GH injections.

Downstream effects of sustained IGF-1 elevation include increased protein synthesis, preferential lipolysis in visceral adipose tissue, and improved lean-mass retention during caloric restriction. The GHRH receptor desensitizes with continuous stimulation, which is the primary clinical reason practitioners use a weekly rather than daily injection schedule for DAC-containing formulations.

MOTS-c: Mitochondrial Metabolic Regulation

MOTS-c (Mitochondrial Open-reading-frame of the twelve S rRNA-c) is a 16-amino-acid peptide encoded entirely within mitochondrial DNA, not nuclear DNA. That origin is unusual; MOTS-c belongs to a class now called mitochondria-derived peptides (MDPs) [2].

Its main signaling target is AMP-activated protein kinase (AMPK). When MOTS-c activates AMPK, cells shift toward fatty-acid oxidation, suppress gluconeogenesis, and increase glucose uptake in skeletal muscle independently of insulin [2]. In a 2021 Nature Aging study in mice, MOTS-c administration reversed age-related insulin resistance and restored exercise capacity in aged animals [3]. The same paper reported that circulating MOTS-c declines with age in humans, and that lower serum MOTS-c correlates with higher fasting glucose and HOMA-IR scores [3].

Human phase-1 data on exogenous MOTS-c injection are limited to small open-label series as of early 2025. No large phase-3 trial has been registered or completed.

Mechanism Combination: How the Two Peptides Interact

Neither peptide directly modulates the other's receptor. Their combined rationale rests on additive rather than synergistic biology, with a few points where the pathways do converge.

Shared Downstream Effect: Insulin Sensitivity

CJC-1295 raises GH, which acutely reduces insulin sensitivity through post-receptor suppression of the PI3K/Akt pathway. Over a longer cycle, however, the body-composition shift (more lean mass, less visceral fat) tends to improve insulin sensitivity on a net basis [4]. MOTS-c activates AMPK directly, improving insulin sensitivity within hours of administration [2]. Stacking the two means MOTS-c may blunt the transient insulin-resistance window that accompanies GH elevation, though no trial has tested this hypothesis directly.

Fat Oxidation

Both peptides support lipolysis through different routes. Elevated IGF-1 and GH suppress lipoprotein lipase in adipose tissue and promote hormone-sensitive lipase activity [4]. MOTS-c increases fatty-acid beta-oxidation in mitochondria by upregulating enzymes in the carnitine shuttle and the tricarboxylic acid cycle [2]. The two mechanisms are not redundant; they act at different steps of the same overall process.

Muscle Protein Synthesis

CJC-1295-driven IGF-1 elevation activates the mTOR/p70S6K pathway in skeletal muscle, directly increasing muscle protein synthesis rates [4]. MOTS-c does not significantly activate mTOR. The AMPK pathway MOTS-c engages is, in some contexts, mTOR-inhibitory. This means the two peptides are not purely additive for muscle protein synthesis, and the net result depends on relative doses, training status, and protein intake. Current evidence does not quantify this interaction.

Dosing Protocol

Because no head-to-head RCT guides dosing for this combination, the protocol below is built from the CJC-1295 dose-escalation data [1], the animal and early-human MOTS-c literature [2,3], and published practitioner guidance reviewed by the HealthRX medical team.

CJC-1295 Dosing Options

With DAC (once-weekly):

• Dose: 1,000 to 2,000 mcg subcutaneous, once per week
• Injection site: abdomen or lateral thigh, rotated
• Timing: morning injection is conventional; timing relative to meals is not established as clinically significant

Without DAC (nightly, pulsatile):

• Dose: 100 to 200 mcg subcutaneous, 5 nights per week
• Timing: 30 to 60 minutes before sleep, when endogenous GH pulse is highest
• Often co-administered with Ipamorelin 200 to 300 mcg to amplify the GH pulse; this is a separate consideration from the MOTS-c stack discussed here

The DAC formulation is generally preferred for convenience and for maintaining stable IGF-1 elevations. The non-DAC formulation preserves a more physiological pulsatile pattern. Practitioners disagree on which is clinically superior; the CJC-1295 DAC phase-2 data showed IGF-1 increases of approximately 28 to 43% above baseline after multiple doses at 30 mcg/kg and 60 mcg/kg [1].

MOTS-c Dosing

• Starting dose: 5 mg subcutaneous, two times per week
• Titration: may increase to 10 mg two to three times per week if tolerability is confirmed after 2 weeks
• Injection timing: morning on training days; timing on rest days is not established as critical
• Reconstitution: MOTS-c is supplied as lyophilized powder; reconstitute with bacteriostatic water to a concentration of 5 mg/mL

MOTS-c has no established human pharmacokinetic profile from large published trials. The 5 to 10 mg range is derived from mouse-to-human allometric scaling of doses used in the 2021 Nature Aging study and from early open-label clinical series referenced in practitioner literature [3].

Combined Weekly Schedule (Example)

| Day | CJC-1295 (with DAC) | MOTS-c | |---|---|---| | Monday | 1,000 to 2,000 mcg | 5 to 10 mg | | Wednesday | None | 5 to 10 mg | | Friday | None | 5 to 10 mg (optional) | | Saturday | None | None | | Sunday | None | None |

Cycle length: 8 weeks minimum to allow IGF-1 levels to stabilize and adipose remodeling to begin. 12 to 16 weeks is more common in practitioner reports. A 4-week off-cycle allows pituitary sensitivity to GHRH to recover before resuming.

Expected Outcomes and Time Course

Outcomes are described below in terms of time horizons, with the evidence base noted explicitly for each claim.

Weeks 1 to 4

IGF-1 rises measurably within 7 to 14 days of the first CJC-1295 injection. In the phase-2 trial, mean IGF-1 increase from baseline was 28% at day 14 with the 30 mcg/kg dose [1]. Sleep quality and recovery often improve before body-composition changes are visible, likely because GH is predominantly secreted during slow-wave sleep [5].

MOTS-c effects on fasting glucose and insulin sensitivity may appear in this window based on the animal data showing improved HOMA-IR within 2 weeks [3], but human data confirming this time course are lacking.

Weeks 5 to 12

Lean mass accretion and visceral fat reduction are typically reported in this range for GH-axis peptides. A meta-analysis of GHRH analogue trials (not specific to CJC-1295) found a mean increase in lean body mass of 1.6 kg and a mean decrease in fat mass of 1.5 kg over 6 months in GH-deficient adults [6]. Effects in eugonadal, non-deficient adults are smaller.

Improved exercise performance and reduced recovery time are commonly reported with MOTS-c in both animal models [3] and practitioner case series, though the magnitude is not established by controlled human trials.

Weeks 13 to 16 and Beyond

IGF-1 plateaus. Continued fat-mass reduction may reflect the compounding of improved insulin sensitivity (MOTS-c contribution) and sustained lipolytic signaling (CJC-1295 contribution). Practitioners typically repeat IGF-1 labs at week 12 to confirm the level has not exceeded the upper reference range for the patient's age and sex.

Lab Monitoring

Monitoring is not optional for this stack. The following labs are standard before starting and at 8 to 12 weeks:

• Baseline: IGF-1 (age- and sex-matched reference range), fasting glucose, fasting insulin, HOMA-IR, HbA1c, lipid panel, CBC, CMP
• Week 8 to 12: Repeat IGF-1, fasting glucose, fasting insulin, HOMA-IR
• Ongoing: IGF-1 every 3 months if continuing beyond one cycle

The Endocrine Society Clinical Practice Guideline on adult GH deficiency states that IGF-1 should remain within the age-normalized reference range during GH-axis therapy and that levels above the upper limit of normal warrant dose reduction [7]. That guidance was written for recombinant GH, not GHRH analogues, but the principle applies here.

Target IGF-1: mid-normal range for age and sex. An IGF-1 that is elevated above the reference range warrants dose reduction or cycle interruption regardless of symptoms.

Safety, Contraindications, and Evidence Gaps

Known Adverse Effects of CJC-1295

The phase-2 trial reported the most common adverse events as injection-site reactions (erythema, pain), flushing, and headache, each occurring in fewer than 15% of participants [1]. Water retention is frequently reported in clinical practice during the first 2 to 4 weeks of GH-axis therapy. Carpal tunnel-like paresthesias are known class effects of GH-axis stimulation and generally resolve with dose reduction.

Sustained supraphysiological IGF-1 is theoretically associated with cancer risk, based on epidemiological data linking high normal-range IGF-1 to colorectal and prostate cancer incidence [8]. The clinical significance of short peptide cycles is unknown, and no trial has demonstrated increased cancer incidence with GHRH-analogue use. Active malignancy is an absolute contraindication.

Known Adverse Effects of MOTS-c

Human safety data for exogenous MOTS-c are limited to small series. No serious adverse events have been formally published in a peer-reviewed journal as of early 2025. The theoretical concern is excessive AMPK activation leading to hypoglycemia, particularly in combination with insulin secretagogues or insulin. Patients on metformin (which also activates AMPK) should use caution, and blood glucose monitoring is advised.

Absolute Contraindications for This Stack

• Active or suspected malignancy
• Uncontrolled type 1 or type 2 diabetes (HbA1c >8.5%)
• Pregnancy or active breastfeeding
• Known pituitary tumor or history of pituitary irradiation
• Proliferative diabetic retinopathy
• Age <18 years

Evidence Gaps

The absence of a head-to-head RCT for this combination is a genuine limitation. Practitioners and patients should weigh the mechanistic rationale against that gap. The FDA has not approved CJC-1295 or MOTS-c for any indication. Both are classified as research compounds. The FDA's position on compounded peptides, including the removal of several from the 503A/503B compounding lists in 2023 and 2024, means legal access through a licensed compounding pharmacy requires a valid practitioner prescription and awareness of current regulatory status [9].

"The data on MOTS-c in humans are promising but embryonic. We are essentially extrapolating from very elegant mouse studies," said Dr. Pinchas Cohen, Dean of the USC Leonard Davis School of Gerontology and one of the original researchers who characterized MOTS-c in 2015 [2]. His research group continues active investigation but has not published phase-2 human efficacy data as of this writing.

Who Is a Candidate for This Stack?

This stack is most appropriate for adults aged 35 to 65 who meet all of the following:

• Documented age-related decline in IGF-1 (low-normal range for age), or functional symptoms consistent with suboptimal GH axis tone (poor sleep quality, slow recovery, progressive fat gain despite stable caloric intake)
• Metabolic phenotype: insulin resistance (HOMA-IR >2.5), impaired fasting glucose (100 to 125 mg/dL), or excess visceral adiposity without overt type-2 diabetes
• No contraindications listed above
• Willing to undergo baseline and follow-up labs and to work with a prescribing clinician

Adults with frank adult-onset GH deficiency confirmed by stimulation testing should discuss recombinant GH with an endocrinologist before considering GHRH analogues. The Endocrine Society defines adult GH deficiency as a peak GH response <3 mcg/L (severe deficiency) or <5 mcg/L (partial deficiency) on a validated stimulation test [7].

Lean, insulin-sensitive adults with normal IGF-1 for age are unlikely to see meaningful body-composition benefits from CJC-1295 and carry the same monitoring burden and theoretical risks as those with documented deficiency.

Stacking with Other Peptides: Considerations

Some practitioners add Ipamorelin (a GH secretagogue that acts at the ghrelin receptor) to CJC-1295 without DAC to amplify the GH pulse. Adding Ipamorelin to a CJC-1295 + MOTS-c protocol is feasible but increases complexity and the number of daily injections. BPC-157, occasionally stacked with MOTS-c for its connective-tissue repair data, has a separate mechanism and is not discussed here.

Stacking CJC-1295 with peptides that also stimulate insulin secretion (e.g., GLP-1 receptor agonists prescribed off-label) requires careful glucose monitoring, given the competing effects of GH-induced insulin resistance and GLP-1-driven insulin secretion.

Regulatory and Sourcing Notes

CJC-1295 and MOTS-c are not FDA-approved drugs. In the United States, they may only be legally dispensed as compounded preparations under a valid prescription from a licensed practitioner. Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act govern compounding pharmacies [9]. Patients should verify that their compounding pharmacy holds PCAB accreditation or equivalent state licensure and that products are tested for sterility, potency, and endotoxins.

Purchasing either peptide from research-chemical vendors without a prescription is legally and medically inadvisable. Purity and sterility are not guaranteed, and dosing accuracy in unregulated products is not verifiable.